Vernon E. Walker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vernon E. Walker has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Dale M. Walker
Lovelace Respiratory Research Institute, Albuquerque, New Mexico
5 shared publicationsQuanxin Meng
Wadsworth Center, New York State Department of Health, Albany, New York, USA
5 shared publicationsMiriam C. Poirier
Carcinogen‐DNA Interactions Section, National Cancer Institute, NIH, Bethesda, Maryland
3 shared publications- Bobby R. Scott
Lovelace Respiratory Research Institute, Albuquerque, NM, USA
2 shared publications Consuelo L. McCash
Lovelace Respiratory Research Institute, Albuquerque, New Mexico
2 shared publications- Dale M. Walker
Lovelace Respiratory Research Institute, Albuquerque, New Mexico, USA
2 shared publications
Latest Publications
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 283-298
Transplacental carcinogenicity of 3′‐azido‐3′‐deoxythymidine in B6C3F1 mice and F344 rats
The prophylactic use of zidovudine (3′‐azido‐3′‐deoxythymidine, AZT) during pregnancy greatly reduces transmission of HIV‐1 from infected mothers to their infants; however, the affinity of host cell DNA polymerases for AZT also allows for its incorporation into host cell DNA, predisposing to cancer development. To expand upon previous transplacental carcinogenesis assays performed in CD‐1 mice, the transplacental carcinogenicity of AZT was evaluated in a second mouse strain and a second rodent species. Date‐mated female mice and rats were gavaged daily with 0, 80, 240, or 480 mg AZT/kg bw during the last 7 days of gestation. At 2 years postpartum, male and female B6C3F1 mouse and F344 rat offspring (n = 44–46 of each sex and species/treatment group) were necropsied for gross and microscopic tissue examinations. Under the conditions of these two‐year studies, there was clear evidence of carcinogenic activity based upon significant dose‐related trends and increases in the incidences of hemangiosarcoma in male mice and mononuclear cell leukemia in female rats. There was some evidence of carcinogenic activity in the livers of male mice based upon a positive trend and an increased incidence of hepatic carcinoma in the high‐dose AZT group. The incidence of gliomas in female rats exceeded the historical background rates for gliomas in F344 rats. P53 overexpression was detected in some AZT‐treated mouse neoplasms. These and other cancer‐related findings confirm and extend those of previous transplacental carcinogenicity studies of AZT in mice, support the need for long‐term follow‐up of nucleoside reverse transcriptase inhibitor (NRTI)‐exposed children, and indicate the necessity for effective protective strategies against NRTI‐induced side effects. Environ. Mol. Mutagen., 2007.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 283-298
Transplacental carcinogenicity of 3′‐azido‐3′‐deoxythymidine in B6C3F1 mice and F344 rats
The prophylactic use of zidovudine (3′‐azido‐3′‐deoxythymidine, AZT) during pregnancy greatly reduces transmission of HIV‐1 from infected mothers to their infants; however, the affinity of host cell DNA polymerases for AZT also allows for its incorporation into host cell DNA, predisposing to cancer development. To expand upon previous transplacental carcinogenesis assays performed in CD‐1 mice, the transplacental carcinogenicity of AZT was evaluated in a second mouse strain and a second rodent species. Date‐mated female mice and rats were gavaged daily with 0, 80, 240, or 480 mg AZT/kg bw during the last 7 days of gestation. At 2 years postpartum, male and female B6C3F1 mouse and F344 rat offspring (n = 44–46 of each sex and species/treatment group) were necropsied for gross and microscopic tissue examinations. Under the conditions of these two‐year studies, there was clear evidence of carcinogenic activity based upon significant dose‐related trends and increases in the incidences of hemangiosarcoma in male mice and mononuclear cell leukemia in female rats. There was some evidence of carcinogenic activity in the livers of male mice based upon a positive trend and an increased incidence of hepatic carcinoma in the high‐dose AZT group. The incidence of gliomas in female rats exceeded the historical background rates for gliomas in F344 rats. P53 overexpression was detected in some AZT‐treated mouse neoplasms. These and other cancer‐related findings confirm and extend those of previous transplacental carcinogenicity studies of AZT in mice, support the need for long‐term follow‐up of nucleoside reverse transcriptase inhibitor (NRTI)‐exposed children, and indicate the necessity for effective protective strategies against NRTI‐induced side effects. Environ. Mol. Mutagen., 2007.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 330-343
Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother–child pairs to AZT or AZT‐3TC
The genotoxicity of zidovudine (AZT) based treatments was investigated in human H9 lymphoblastoid cells in an in vitro study and in red blood cells (RBCs) from perinatally exposed HIV‐1‐infected mothers and their infants in an observational cohort study. Exposure of H9 cells for 24 hr to AZT produced dose‐dependent increases in Comet assay tail moment (TM) when electrophoresed at pH 13.0, but not at pH 12.1 or pH 8.0, suggesting that DNA damage was via alkali‐labile lesions and not double‐stranded DNA strand breaks. The TM dose response at pH 13.0 correlated directly with AZT‐DNA incorporation determined by AZT‐radioimmunoassay. Levels of DNA damage in utero, measured by Comet assay TM, were similar in cord blood mononuclear cells of nucleoside analog‐exposed newborns (n = 43) and unexposed controls (n = 40). In contrast, the glycophorin A (GPA) somatic cell mutation assay (which screens for large‐scale DNA damage in RBCs) showed clear evidence that GPA N/N variants, arising from chromosome loss and duplication, somatic recombination, and gene conversion, were significantly elevated in mother–child pairs receiving prepartum AZT plus lamivudine (3TC). Cord blood from newborns exposed to AZT‐3TC had GPA N/N variant frequencies of 4.7 ± 0.7 (mean ± SE) × 10−6 RBCs (n = 26 infants) compared with 2.2 ± 0.3 × 10−6 RBCs for unexposed controls (n = 30 infants; P < 0.001). Elevations in GPA N/N variants generally persisted through 1 year of age in nucleoside analog‐exposed children. Overall, the mutagenic effects found in mother–child pairs receiving AZT‐based treatments justify their surveillance for long‐term genotoxic consequences. Environ. Mol. Mutagen., 2007.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 330-343
Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother–child pairs to AZT or AZT‐3TC
The genotoxicity of zidovudine (AZT) based treatments was investigated in human H9 lymphoblastoid cells in an in vitro study and in red blood cells (RBCs) from perinatally exposed HIV‐1‐infected mothers and their infants in an observational cohort study. Exposure of H9 cells for 24 hr to AZT produced dose‐dependent increases in Comet assay tail moment (TM) when electrophoresed at pH 13.0, but not at pH 12.1 or pH 8.0, suggesting that DNA damage was via alkali‐labile lesions and not double‐stranded DNA strand breaks. The TM dose response at pH 13.0 correlated directly with AZT‐DNA incorporation determined by AZT‐radioimmunoassay. Levels of DNA damage in utero, measured by Comet assay TM, were similar in cord blood mononuclear cells of nucleoside analog‐exposed newborns (n = 43) and unexposed controls (n = 40). In contrast, the glycophorin A (GPA) somatic cell mutation assay (which screens for large‐scale DNA damage in RBCs) showed clear evidence that GPA N/N variants, arising from chromosome loss and duplication, somatic recombination, and gene conversion, were significantly elevated in mother–child pairs receiving prepartum AZT plus lamivudine (3TC). Cord blood from newborns exposed to AZT‐3TC had GPA N/N variant frequencies of 4.7 ± 0.7 (mean ± SE) × 10−6 RBCs (n = 26 infants) compared with 2.2 ± 0.3 × 10−6 RBCs for unexposed controls (n = 30 infants; P < 0.001). Elevations in GPA N/N variants generally persisted through 1 year of age in nucleoside analog‐exposed children. Overall, the mutagenic effects found in mother–child pairs receiving AZT‐based treatments justify their surveillance for long‐term genotoxic consequences. Environ. Mol. Mutagen., 2007.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 159-165
Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 159-165
Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 224-238
Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD‐1 mice to single agents or drug combinations
Experiments were performed to investigate the impact of zidovudine (AZT), lamivudine (3TC), and abacavir (ABC) on cell survival and mutagenicity in two reporter genes, hypoxanthine‐guanine phosphoribosyltransferase (HPRT) and thymidine kinase (TK), using cell cloning assays for assessing the effects of individual drugs/drug combinations in (1) TK6 human lymphoblastoid cells exposed in vitro and (2) splenic lymphocytes from male CD‐1 mice exposed transplacentally on days 12–18 of gestation. In TK6 cells, dose‐related increases in HPRT and TK mutant frequencies were found following 3 days of exposure to AZT or 3TC alone (33, 100, or 300 μM), or to equimolar amounts of AZT‐3TC. Compared with single drug exposures, AZT‐3TC coexposures generally yielded enhanced elevations in HPRT and TK mutant frequencies. Mutagenicity experiments with ABC alone, or in combination with AZT‐3TC, were complicated by the extreme cytotoxicity of ABC. Exposure of cells either to relatively high levels of AZT‐3TC short‐term (100 μM, 3 days), or to peak plasma‐equivalent levels of AZT‐3TC for an extended period (10 μM, 30 days), resulted in similar drug‐induced mutagenic responses. Among sets of mice necropsied on days 13, 15, or 21 postpartum, Hprt mutant frequencies in T‐cells were significantly elevated in the AZT‐only (200 mg/kg bw/day) and AZT‐3TC (200 mg AZT + 100 mg 3TC/kg bw/day) groups at 13 days of age. These results suggest that the mutagenicity by these nucleoside analogs is driven by cumulative dose, and raises the question of whether AZT‐3TC has greater mutagenic effects than AZT alone in perinatally exposed children. Environ. Mol. Mutagen.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 224-238
Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD‐1 mice to single agents or drug combinations
Experiments were performed to investigate the impact of zidovudine (AZT), lamivudine (3TC), and abacavir (ABC) on cell survival and mutagenicity in two reporter genes, hypoxanthine‐guanine phosphoribosyltransferase (HPRT) and thymidine kinase (TK), using cell cloning assays for assessing the effects of individual drugs/drug combinations in (1) TK6 human lymphoblastoid cells exposed in vitro and (2) splenic lymphocytes from male CD‐1 mice exposed transplacentally on days 12–18 of gestation. In TK6 cells, dose‐related increases in HPRT and TK mutant frequencies were found following 3 days of exposure to AZT or 3TC alone (33, 100, or 300 μM), or to equimolar amounts of AZT‐3TC. Compared with single drug exposures, AZT‐3TC coexposures generally yielded enhanced elevations in HPRT and TK mutant frequencies. Mutagenicity experiments with ABC alone, or in combination with AZT‐3TC, were complicated by the extreme cytotoxicity of ABC. Exposure of cells either to relatively high levels of AZT‐3TC short‐term (100 μM, 3 days), or to peak plasma‐equivalent levels of AZT‐3TC for an extended period (10 μM, 30 days), resulted in similar drug‐induced mutagenic responses. Among sets of mice necropsied on days 13, 15, or 21 postpartum, Hprt mutant frequencies in T‐cells were significantly elevated in the AZT‐only (200 mg/kg bw/day) and AZT‐3TC (200 mg AZT + 100 mg 3TC/kg bw/day) groups at 13 days of age. These results suggest that the mutagenicity by these nucleoside analogs is driven by cumulative dose, and raises the question of whether AZT‐3TC has greater mutagenic effects than AZT alone in perinatally exposed children. Environ. Mol. Mutagen.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 307-321
Plasma and cellular markers of 3′‐azido‐3′‐dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs
Several systemic and cellular markers of 3′‐azido‐3′‐dideoxythymidine (AZT) metabolism and AZT incorporation into nuclear DNA were measured in cord blood from uninfected infants born to HIV‐1‐infected mothers receiving prepartum therapies based on AZT or AZT in combination with 2′,3′‐dideoxy‐3′‐thiacytidine (3TC). In addition, the relationships among these pharmacological end points, levels of AZT‐DNA incorporation, and the previously reported mutagenic responses in these infants were evaluated. AZT‐ and 3TC‐specific radioimmunoassays (RIAs), or HPLC coupled with AZT‐RIA, were used to measure plasma levels of AZT and the AZT‐glucuronide, and cellular levels of AZT, phosphorylated AZT, and DNA incorporation of AZT or 3TC in cord blood mononuclear cells from treated infants compared with unexposed controls born to HIV‐uninfected mothers. Fewer infants had detectable AZT‐DNA incorporation levels in the group exposed to AZT (71%; n = 7) compared with those receiving AZT‐3TC (100%; n = 21), and the mean AZT‐DNA incorporation for AZT‐exposed infants (14.6 ± 6.3 AZT/106 nucleotides) was significantly lower than that in AZT‐3TC exposed infants (51.6 ± 10.2 AZT/106 nucleotides; P = 0.028). Low levels of 3TC‐DNA incorporation found in a few AZT‐3TC‐exposed newborns correlated with AZT‐DNA incorporation values in the same samples. Among the metabolites studied, there were positive correlations between levels of AZT‐diphosphate and AZT‐triphosphate, and AZT‐triphosphate and AZT‐DNA incorporation, in nucleoside analog‐exposed infants. Levels of AZT‐DNA incorporation, however, did not correlate well with the reported frequencies of somatic mutations in the same population of nucleoside analog‐treated children. While these data support the continued use of AZT‐based therapies during pregnancy, infants receiving prepartum AZT should be monitored long‐term for adverse health effects. Environ. Mol. Mutagen., 2007.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 307-321
Plasma and cellular markers of 3′‐azido‐3′‐dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs
Several systemic and cellular markers of 3′‐azido‐3′‐dideoxythymidine (AZT) metabolism and AZT incorporation into nuclear DNA were measured in cord blood from uninfected infants born to HIV‐1‐infected mothers receiving prepartum therapies based on AZT or AZT in combination with 2′,3′‐dideoxy‐3′‐thiacytidine (3TC). In addition, the relationships among these pharmacological end points, levels of AZT‐DNA incorporation, and the previously reported mutagenic responses in these infants were evaluated. AZT‐ and 3TC‐specific radioimmunoassays (RIAs), or HPLC coupled with AZT‐RIA, were used to measure plasma levels of AZT and the AZT‐glucuronide, and cellular levels of AZT, phosphorylated AZT, and DNA incorporation of AZT or 3TC in cord blood mononuclear cells from treated infants compared with unexposed controls born to HIV‐uninfected mothers. Fewer infants had detectable AZT‐DNA incorporation levels in the group exposed to AZT (71%; n = 7) compared with those receiving AZT‐3TC (100%; n = 21), and the mean AZT‐DNA incorporation for AZT‐exposed infants (14.6 ± 6.3 AZT/106 nucleotides) was significantly lower than that in AZT‐3TC exposed infants (51.6 ± 10.2 AZT/106 nucleotides; P = 0.028). Low levels of 3TC‐DNA incorporation found in a few AZT‐3TC‐exposed newborns correlated with AZT‐DNA incorporation values in the same samples. Among the metabolites studied, there were positive correlations between levels of AZT‐diphosphate and AZT‐triphosphate, and AZT‐triphosphate and AZT‐DNA incorporation, in nucleoside analog‐exposed infants. Levels of AZT‐DNA incorporation, however, did not correlate well with the reported frequencies of somatic mutations in the same population of nucleoside analog‐treated children. While these data support the continued use of AZT‐based therapies during pregnancy, infants receiving prepartum AZT should be monitored long‐term for adverse health effects. Environ. Mol. Mutagen., 2007.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 239-247
Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells
Experiments were performed to investigate the impact of didanosine (ddI), lamivudine (3TC), and stavudine (d4T) on cell survival and mutagenicity in two reporter genes, hypoxanthine‐guanine phosphoribosyltransferase (HPRT) and thymidine kinase (TK), using a cell cloning assay for assessing the effects of individual nucleoside analogs (NRTIs)/drug combinations in human TK6 B‐lymphoblastoid cells. Three‐day treatments with 0, 33, 100, or 300 μM ddI, 3TC, or ddI‐3TC produced positive trends for increased HPRT and TK mutant frequencies. While dose‐related trends were too small to reach significance after treatments with d4T or d4T‐3TC, pairwise comparisons with control cells indicated that exposure to 100 μM d4T or d4T‐3TC caused significant elevations in HPRT mutants. Measurements of mutagenicity in cells exposed to d4T (or d4T‐3TC) were complicated by the cytotoxicity of this NRTI. Enhanced increases in mutagenic responses to combined NRTI treatments, compared with single drug treatments, occurred as additive to synergistic effects in the HPRT gene of cells exposed to 100 μM ddI‐3TC or 100 μM d4T‐3TC, and in the TK gene of cells exposed to 100 or 300 μM ddI‐3TC. Comparisons of these data to mutagenicity studies of other NRTIs in the same system (Meng Q et al. [2000c]: Proc Natl Acad Sci USA 97:12667–126671; Torres SM et al. [2007]: Environ Mol Mutagen) indicate that the relative mutagenic potencies for all drugs tested to date are: AZT‐ddI > ddI‐3TC > AZT‐3TC ≅ AZT‐3TC‐ABC (abacavir) > AZT ≥ddI > d4T‐3TC > 3TC > d4T ≥ ABC. These collective data suggest that all NRTIs with antiviral activity against HIV‐1 may cause host cell DNA damage and mutations, and impose a cancer risk. Environ. Mol. Mutagen., 2007.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 239-247
Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells
Experiments were performed to investigate the impact of didanosine (ddI), lamivudine (3TC), and stavudine (d4T) on cell survival and mutagenicity in two reporter genes, hypoxanthine‐guanine phosphoribosyltransferase (HPRT) and thymidine kinase (TK), using a cell cloning assay for assessing the effects of individual nucleoside analogs (NRTIs)/drug combinations in human TK6 B‐lymphoblastoid cells. Three‐day treatments with 0, 33, 100, or 300 μM ddI, 3TC, or ddI‐3TC produced positive trends for increased HPRT and TK mutant frequencies. While dose‐related trends were too small to reach significance after treatments with d4T or d4T‐3TC, pairwise comparisons with control cells indicated that exposure to 100 μM d4T or d4T‐3TC caused significant elevations in HPRT mutants. Measurements of mutagenicity in cells exposed to d4T (or d4T‐3TC) were complicated by the cytotoxicity of this NRTI. Enhanced increases in mutagenic responses to combined NRTI treatments, compared with single drug treatments, occurred as additive to synergistic effects in the HPRT gene of cells exposed to 100 μM ddI‐3TC or 100 μM d4T‐3TC, and in the TK gene of cells exposed to 100 or 300 μM ddI‐3TC. Comparisons of these data to mutagenicity studies of other NRTIs in the same system (Meng Q et al. [2000c]: Proc Natl Acad Sci USA 97:12667–126671; Torres SM et al. [2007]: Environ Mol Mutagen) indicate that the relative mutagenic potencies for all drugs tested to date are: AZT‐ddI > ddI‐3TC > AZT‐3TC ≅ AZT‐3TC‐ABC (abacavir) > AZT ≥ddI > d4T‐3TC > 3TC > d4T ≥ ABC. These collective data suggest that all NRTIs with antiviral activity against HIV‐1 may cause host cell DNA damage and mutations, and impose a cancer risk. Environ. Mol. Mutagen., 2007.
- 1 January 2004
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 43 (2) , 75-92
Characterization ofHprtmutations in cDNA and genomic DNA of T‐cell mutants from control and 1,3‐butadiene‐exposed male B6C3F1 mice and F344 rats
A multiplex PCR procedure for analysis of genomic DNA mutations in the mouse hypoxanthine-guanine phosphoribosyltransferase (Hprt) gene was developed and then used with other established methods for the coincident identification of large- and small-scale genetic alterations in the Hprt gene of mutant T-cell isolates propagated from sham- and 1,3-butadiene (BD)-exposed mice and rats. The spectra data for RT-PCR/cDNA analysis and multiplex PCR of genomic DNA from Hprt mutants were combined, and statistical analyses of the mutant fractions for the classes of mutations identified in control versus exposed animals were conducted. Under the assumption that the mutant fractions are distributed as Poisson variates, BD exposure of mice significantly increased the frequencies of (1) nearly all types of base substitutions; (2) single-base deletions and insertions; and (3) all subcategories of deletions. Significantly elevated fractions of G:C→C:G and A:T→T:A transversions in the Hprt gene of BD-exposed mice were consistent with the occurrence of these substitutions as the predominant ras gene mutations in multiple tumor types increased in incidence in carcinogenicity studies of BD in mice. BD exposure of rats produced significant increases in (1) base substitutions only at A:T base pairs; (2) single-base insertions; (3) complex mutations; and (4) deletions (mainly 5′ partial and complete gene deletions). Future coincident analyses of large- and small-scale mutations in rodents exposed to specific BD metabolites should help identify species differences in the sources of deletion mutations and other types of mutations induced by BD exposures in mice versus rats. Environ. Mol. Mutagen. 43:75–92, 2004.
- 1 January 2004
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 43 (2) , 75-92
Characterization ofHprtmutations in cDNA and genomic DNA of T‐cell mutants from control and 1,3‐butadiene‐exposed male B6C3F1 mice and F344 rats
A multiplex PCR procedure for analysis of genomic DNA mutations in the mouse hypoxanthine-guanine phosphoribosyltransferase (Hprt) gene was developed and then used with other established methods for the coincident identification of large- and small-scale genetic alterations in the Hprt gene of mutant T-cell isolates propagated from sham- and 1,3-butadiene (BD)-exposed mice and rats. The spectra data for RT-PCR/cDNA analysis and multiplex PCR of genomic DNA from Hprt mutants were combined, and statistical analyses of the mutant fractions for the classes of mutations identified in control versus exposed animals were conducted. Under the assumption that the mutant fractions are distributed as Poisson variates, BD exposure of mice significantly increased the frequencies of (1) nearly all types of base substitutions; (2) single-base deletions and insertions; and (3) all subcategories of deletions. Significantly elevated fractions of G:C→C:G and A:T→T:A transversions in the Hprt gene of BD-exposed mice were consistent with the occurrence of these substitutions as the predominant ras gene mutations in multiple tumor types increased in incidence in carcinogenicity studies of BD in mice. BD exposure of rats produced significant increases in (1) base substitutions only at A:T base pairs; (2) single-base insertions; (3) complex mutations; and (4) deletions (mainly 5′ partial and complete gene deletions). Future coincident analyses of large- and small-scale mutations in rodents exposed to specific BD metabolites should help identify species differences in the sources of deletion mutations and other types of mutations induced by BD exposures in mice versus rats. Environ. Mol. Mutagen. 43:75–92, 2004.
- 1 January 2004
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 43 (4) , 265-272
Hprt mutant frequencies in splenic T‐cells of male F344 rats exposed by inhalation to propylene
Propylene is a major industrial intermediate and atmospheric pollutant to which humans are exposed by inhalation. In this study, 6‐week‐old male F344 rates were exposed to 0, 200, 2000, or 10,000 ppm propylene by inhalation for 4 weeks (6 h/day, 5 days/week), and mutant frequencies were determined in the Hprt gene of splenic T‐lymphocytes. Twenty milligrams of cyclophosphamide monohydrate (CPP)/kg bw, given on the penultimate day of propylene exposure, was used as a positive control mutagen. Rats (n = 8/group) were necropsied for isolation of T‐cells 8 weeks after the last dose, a sampling time that produced peak spleen Hprt mutant frequencies (Mfs) in a preliminary mutant manifestation study using CCP treatment. Hprt Mfs were measured via the T‐cell cloning assay, which was performed without knowledge of the animal treatment groups. Mean Hprt Mfs were significantly increased over control values (mean Mf = 5.24 ± 1.55 (SD) × 10−6) in CPP‐treated rats (10.37 ± 4.30 × 10−6, P = 0.007). However, Hprt Mfs in propylene‐exposed rats were not significantly increased over background, with mean Mfs of 4.90 ± 1.84 × 10−6 (P = 0.152), 5.05 ± 3.70 × 10−6 (P = 0.895), and 5.95 ± 2.49 ×10−6 (P = 0.500) for animals exposed to 200, 2000, or 10,000 ppm propylene, respectively. No significant increase in F344 rat or B6C3F1 mouse cancer incidence was reported in the National Toxicology Program carcinogenicity studies of propylene across this same exposure range. Taken together, these findings support the conclusion that inhalation exposure of rats to propylene does not cause mutations or cancer. Environ. Mol. Mutagen. 43:265–272, 2004.
- 1 January 2004
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 43 (4) , 265-272
Hprt mutant frequencies in splenic T‐cells of male F344 rats exposed by inhalation to propylene
Propylene is a major industrial intermediate and atmospheric pollutant to which humans are exposed by inhalation. In this study, 6‐week‐old male F344 rates were exposed to 0, 200, 2000, or 10,000 ppm propylene by inhalation for 4 weeks (6 h/day, 5 days/week), and mutant frequencies were determined in the Hprt gene of splenic T‐lymphocytes. Twenty milligrams of cyclophosphamide monohydrate (CPP)/kg bw, given on the penultimate day of propylene exposure, was used as a positive control mutagen. Rats (n = 8/group) were necropsied for isolation of T‐cells 8 weeks after the last dose, a sampling time that produced peak spleen Hprt mutant frequencies (Mfs) in a preliminary mutant manifestation study using CCP treatment. Hprt Mfs were measured via the T‐cell cloning assay, which was performed without knowledge of the animal treatment groups. Mean Hprt Mfs were significantly increased over control values (mean Mf = 5.24 ± 1.55 (SD) × 10−6) in CPP‐treated rats (10.37 ± 4.30 × 10−6, P = 0.007). However, Hprt Mfs in propylene‐exposed rats were not significantly increased over background, with mean Mfs of 4.90 ± 1.84 × 10−6 (P = 0.152), 5.05 ± 3.70 × 10−6 (P = 0.895), and 5.95 ± 2.49 ×10−6 (P = 0.500) for animals exposed to 200, 2000, or 10,000 ppm propylene, respectively. No significant increase in F344 rat or B6C3F1 mouse cancer incidence was reported in the National Toxicology Program carcinogenicity studies of propylene across this same exposure range. Taken together, these findings support the conclusion that inhalation exposure of rats to propylene does not cause mutations or cancer. Environ. Mol. Mutagen. 43:265–272, 2004.
- 1 January 2002
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 39 (4) , 282-295
Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3′‐azido‐3′‐deoxythymidine and 2′,3′‐dideoxyinosine†
Combinations of antiretroviral drugs that include nucleoside reverse transcriptase inhibitors (NRTIs) are superior to single‐agent regimens in treating or preventing HIV infection, but the potential long‐term health hazards of these treatments in humans are uncertain. In earlier studies, our group found that coexposure of TK6 human lymphoblastoid cells to 3′‐azido‐2′,3′‐dideoxythymidine (AZT) and 2′,3′‐dideoxyinosine (ddI), the first two NRTIs approved by the FDA as antiretroviral drugs, produced multiplicative synergistic enhancement of DNA incorporation of AZT and mutagenic responses in both the HPRT and TK reporter genes, as compared with single‐drug exposures (Meng Q et al. [2000a]: Proc Natl Acad Sci USA 97:12667–12671). The purpose of the current study was to characterize the mutational specificity of equimolar mixtures of 100 μM or 300 μM AZT + ddI at the HPRT and TK loci of exposed cells vs. unexposed control cells, and to compare the resulting mutational spectra data to those previously found in cells exposed to AZT alone (Sussman H et al. [1999]: Mutat Res 429:249–259; Meng Q et al. [2000b]: Toxicol Sci 54:322–329). Molecular analyses of HPRT mutant clones were performed by reverse transcription–mediated production of cDNA, PCR amplification, and cDNA sequencing to define small DNA alterations, followed by multiplex PCR amplification of genomic DNA to define the fractions of deletion events. TK mutants with complete gene deletions were distinguished by Southern blot analysis. The observed HPRT mutational categories included point mutations, microinsertions/microdeletions, splicing‐error mutations, and macrodeletions including partial and complete gene deletions. The only significant difference or shift in the mutational spectra for NRTI‐treated cells vs. control cells was the increase in the frequency of complete TK gene deletions following exposures (for 3 days) to 300 μM AZT–ddI (P = 0.034, chi‐square test of homogeneity); however, statistical analyses comparing the observed mutant fraction values (measured mutant frequency × percent of a class of mutation) between control and NRTI‐treated cells for each class of mutation showed that the occurrences of complete gene deletions of both HPRT and TK were significantly elevated over background values (0.34 × 10−6 in HPRT and 6.0 × 10−6 in TK) at exposure levels of 100 μM AZT–ddI (i.e., 1.94 × 10−6 in HPRT and 18.6 × 10−6 in TK) and 300 μM AZT–ddI (i.e., 5.6 × 10−6 in HPRT and 34.6 × 10−6 in TK) (P < 0.05, Mann–Whitney U‐statistic). These treatment‐related increases in complete gene deletions were consistent with the spectra data for AZT alone (ibid.) and with the known mode of action of AZT and ddI as DNA chain terminators. In addition, cotreatments of ddI with AZT led to substantial absolute increases in the mutant fraction of other classes of mutations, unlike cells exposed solely to AZT [e.g., the frequency of point mutations among HPRT mutants was significantly increased by 130 and 323% over the background value (4.25 × 10−6) in cells exposed to 100 and 300 μM AZT–ddI, respectively]. These results indicate that, at the same time that AZT–ddI potentiates therapeutic or prophylactic efficacy, the use of a second NRTI with AZT may confer a greater cancer risk, characterized by a spectrum of mutations that deviates from that produced solely by AZT. Environ. Mol. Mutagen. 39:282–295, 2002. Published 2002 Wiley‐Liss, Inc.
- 1 January 2002
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 39 (4) , 282-295
Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3′‐azido‐3′‐deoxythymidine and 2′,3′‐dideoxyinosine†
Combinations of antiretroviral drugs that include nucleoside reverse transcriptase inhibitors (NRTIs) are superior to single‐agent regimens in treating or preventing HIV infection, but the potential long‐term health hazards of these treatments in humans are uncertain. In earlier studies, our group found that coexposure of TK6 human lymphoblastoid cells to 3′‐azido‐2′,3′‐dideoxythymidine (AZT) and 2′,3′‐dideoxyinosine (ddI), the first two NRTIs approved by the FDA as antiretroviral drugs, produced multiplicative synergistic enhancement of DNA incorporation of AZT and mutagenic responses in both the HPRT and TK reporter genes, as compared with single‐drug exposures (Meng Q et al. [2000a]: Proc Natl Acad Sci USA 97:12667–12671). The purpose of the current study was to characterize the mutational specificity of equimolar mixtures of 100 μM or 300 μM AZT + ddI at the HPRT and TK loci of exposed cells vs. unexposed control cells, and to compare the resulting mutational spectra data to those previously found in cells exposed to AZT alone (Sussman H et al. [1999]: Mutat Res 429:249–259; Meng Q et al. [2000b]: Toxicol Sci 54:322–329). Molecular analyses of HPRT mutant clones were performed by reverse transcription–mediated production of cDNA, PCR amplification, and cDNA sequencing to define small DNA alterations, followed by multiplex PCR amplification of genomic DNA to define the fractions of deletion events. TK mutants with complete gene deletions were distinguished by Southern blot analysis. The observed HPRT mutational categories included point mutations, microinsertions/microdeletions, splicing‐error mutations, and macrodeletions including partial and complete gene deletions. The only significant difference or shift in the mutational spectra for NRTI‐treated cells vs. control cells was the increase in the frequency of complete TK gene deletions following exposures (for 3 days) to 300 μM AZT–ddI (P = 0.034, chi‐square test of homogeneity); however, statistical analyses comparing the observed mutant fraction values (measured mutant frequency × percent of a class of mutation) between control and NRTI‐treated cells for each class of mutation showed that the occurrences of complete gene deletions of both HPRT and TK were significantly elevated over background values (0.34 × 10−6 in HPRT and 6.0 × 10−6 in TK) at exposure levels of 100 μM AZT–ddI (i.e., 1.94 × 10−6 in HPRT and 18.6 × 10−6 in TK) and 300 μM AZT–ddI (i.e., 5.6 × 10−6 in HPRT and 34.6 × 10−6 in TK) (P < 0.05, Mann–Whitney U‐statistic). These treatment‐related increases in complete gene deletions were consistent with the spectra data for AZT alone (ibid.) and with the known mode of action of AZT and ddI as DNA chain terminators. In addition, cotreatments of ddI with AZT led to substantial absolute increases in the mutant fraction of other classes of mutations, unlike cells exposed solely to AZT [e.g., the frequency of point mutations among HPRT mutants was significantly increased by 130 and 323% over the background value (4.25 × 10−6) in cells exposed to 100 and 300 μM AZT–ddI, respectively]. These results indicate that, at the same time that AZT–ddI potentiates therapeutic or prophylactic efficacy, the use of a second NRTI with AZT may confer a greater cancer risk, characterized by a spectrum of mutations that deviates from that produced solely by AZT. Environ. Mol. Mutagen. 39:282–295, 2002. Published 2002 Wiley‐Liss, Inc.
- 1 January 2001
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 38 (1) , 30-37
Transplacental mutagenicity of N‐ethyl‐N‐nitrosourea at the hprt locus in T‐lymphocytes of exposed B6C3F1 mice
Previous studies have compared age‐related differences in total mutagenic burden in mice of differing age (preweanling, weanling, or young adult) after single intraperitoneal (i.p.) injections of ethylnitrosourea (ENU). The purpose of the present investigation was to determine the effects of time elapsed since treatment on the frequency of hprt mutant T‐cells (Mf) from mice treated transplacentally with single acute vs. multiple split doses of ENU. To this end, pregnant C57BL/6 mice (n = 13–16/group), which had been bred to C3H males, were given i.p. injections of 40 mg ENU/kg bw in a single dose on day 18 of gestation, in a split dose of 6 mg ENU/kg bw on days 12 through 18 of gestation, or DMSO vehicle alone. Groups of pups were necropsied on days 10, 13, 15 (single dose only), 17, 20, 40, and 70 postpartum for T‐cell isolations and hprt Mf measurements using the T‐cell cloning assay. The time required to reach maximum Mfs in T‐cells isolated from thymus of transplacentally treated animals was 2 weeks, the same time span as previously observed after ENU treatment of adult, weanling, and preweanling mice. Mfs in T‐cells isolated from spleens of control animals averaged 2.1 ± 0.3 (SE) × 10−6. In spleens of mice treated transplacentally with ENU in a single dose, Mfs reached a maximum at 15 days postpartum [84.7 ± 15.8 (SE) × 10−6] and decreased to lower but still elevated levels at 40 days postpartum. In spleens of mice treated transplacentally with ENU in a split dose, Mfs reached a maximum at 13 days postpartum [74.0 ± 16.3 (SE) × 10−6] and decreased to background levels at 40 days postpartum. The areas under the curves describing the change in hprt Mfs over time for ENU‐treated vs. control mice estimate the mutagenic potency for transplacental single‐ and split‐dose exposures to be 1.9 and 0.8 × 103, respectively. Comparison of the mutagenic potency estimates for mice exposed to ENU in utero to 4‐week‐old mice given a similar dose of the same lot number of ENU indicates that the mouse is more susceptible to ENU‐induced mutagenesis during fetal life. Environ. Mol. Mutagen. 38:30–37, 2001
- 1 January 2001
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 38 (1) , 30-37
Transplacental mutagenicity of N‐ethyl‐N‐nitrosourea at the hprt locus in T‐lymphocytes of exposed B6C3F1 mice
Previous studies have compared age‐related differences in total mutagenic burden in mice of differing age (preweanling, weanling, or young adult) after single intraperitoneal (i.p.) injections of ethylnitrosourea (ENU). The purpose of the present investigation was to determine the effects of time elapsed since treatment on the frequency of hprt mutant T‐cells (Mf) from mice treated transplacentally with single acute vs. multiple split doses of ENU. To this end, pregnant C57BL/6 mice (n = 13–16/group), which had been bred to C3H males, were given i.p. injections of 40 mg ENU/kg bw in a single dose on day 18 of gestation, in a split dose of 6 mg ENU/kg bw on days 12 through 18 of gestation, or DMSO vehicle alone. Groups of pups were necropsied on days 10, 13, 15 (single dose only), 17, 20, 40, and 70 postpartum for T‐cell isolations and hprt Mf measurements using the T‐cell cloning assay. The time required to reach maximum Mfs in T‐cells isolated from thymus of transplacentally treated animals was 2 weeks, the same time span as previously observed after ENU treatment of adult, weanling, and preweanling mice. Mfs in T‐cells isolated from spleens of control animals averaged 2.1 ± 0.3 (SE) × 10−6. In spleens of mice treated transplacentally with ENU in a single dose, Mfs reached a maximum at 15 days postpartum [84.7 ± 15.8 (SE) × 10−6] and decreased to lower but still elevated levels at 40 days postpartum. In spleens of mice treated transplacentally with ENU in a split dose, Mfs reached a maximum at 13 days postpartum [74.0 ± 16.3 (SE) × 10−6] and decreased to background levels at 40 days postpartum. The areas under the curves describing the change in hprt Mfs over time for ENU‐treated vs. control mice estimate the mutagenic potency for transplacental single‐ and split‐dose exposures to be 1.9 and 0.8 × 103, respectively. Comparison of the mutagenic potency estimates for mice exposed to ENU in utero to 4‐week‐old mice given a similar dose of the same lot number of ENU indicates that the mouse is more susceptible to ENU‐induced mutagenesis during fetal life. Environ. Mol. Mutagen. 38:30–37, 2001